(Pfizer) Pfizer Inc. has announced that its novel Covid-19 antiviral drug candidate PAXLOVID reduces the risk of death or hospitalization by 89%. In an interim study, Pfizer found that no…
(Pfizer) Pfizer announced that it is expecting $36 billion in vaccine sales revenue by the close of the year and $29 billion next year with the increasing vaccine shipment. Pfizer's…
(CNBC) US Food and Drug Administration has granted full approval of Pfizer-BioNTech Covid-19 shots. The approval means that Pfizer and BioNTech become the first in the US to win full…
(Bloomberg) US Food and Drug Administration has allowed Moderna Inc., Pfizer Inc., and BioNTech SE vaccines to be given as a third dose to Americans with weak immune systems. The…
(Financial Times) Vaccine makers Pfizer Inc. and Moderna Inc. have raised their Covid-19 vaccine prices days after signing new supply contracts in the European Union. Pfizer’s short will now sell…
(Reuters) Pfizer has raised its forecasts of sales of joint vaccines with BioNTech by 28.8% to $35.5 billion. The upgraded Covid-19 vaccine sales reflects signed deals of 2.1 billion doses…
Pfizer expects to sell about $15 billion in coronavirus vaccine doses in 2021, according to the company’s press release. The drugmaker forecasts its revenue to be in the range of…
Sanofi is set to produce more than 125 million doses of BioNTech and Pfizer coronavirus vaccine after collaboration, according to Bloomberg. The French drugmaker will give BioNTech access to a…
The European Union cleared Pfizer and BioNTech vaccine on Monday, paving the way for mass vaccinations after Christmas, according to Reuters. Germany, France, Austria, and Italy plan to start vaccinations…
U.S. Pfizer and its German partner BioNTech have applied to the European Medicines Agency (EMA) for the authorization of the BNT162b2 vaccine candidate, according to press release. If approved, the…
Goldman Sachs sees a “very bullish” stock market in the wake of a coronavirus vaccine, according to Yahoo! finance. David Kostin, Goldman’s chief strategist, raised the year-end S&P 500 price…
Pfizer and BioNTech SE’s mRNA-based vaccine candidate BNT162b2 is 90% effective in preventing COVID-19 in participants without prior evidence of SARS-COV-2 infection, according to the company’s press release. The results…